Overview
A small number of clinical trials have examined Boswellia serrata extracts in individuals with bronchial asthma. The mechanistic rationale — that 5-LOX inhibition by boswellic acids might reduce leukotriene synthesis, which is implicated in airway inflammation — provided the basis for investigating a potential respiratory application. However, the clinical evidence base is limited in size and has not been independently replicated.
Asthma is a serious medical condition managed by a qualified healthcare provider. The research summarized here does not establish Boswellia as a treatment for asthma, and should not be used to substitute or modify prescribed asthma therapy.
Key Published Trial
The most-cited study is a double-blind, placebo-controlled trial by Gupta et al. (1998) involving 80 participants with bronchial asthma. Participants received either a standardized Boswellia serrata extract (300 mg three times daily) or placebo for 6 weeks. Authors reported that 70% of participants in the Boswellia group showed improvement in symptoms and lung function parameters (FEV1, peak expiratory flow rate), compared to 27% in the placebo group — a statistically significant difference.
This is an encouraging finding, but must be interpreted in context: the trial enrolled 80 participants at a single site, used an extract that may differ from modern standardized formulations, and has not been independently replicated in a similarly designed trial.
- Statistically significant improvement in symptom scores and lung function vs. placebo in one RCT (n=80)
- 70% vs. 27% responder rate in Boswellia vs. placebo groups
- 6-week treatment duration
- Whether the single positive trial would replicate in independent studies
- Efficacy as add-on therapy to standard asthma medications
- Long-term outcomes and safety in asthma
- Applicable extract type, dose, and standardization